neonatal cardiac progenitor cells

funding

North Texas’ Secretome Therapeutics Raises $30M Series A to Advance Muscular Dystrophy-Related Drug

by | May 28, 2026
The financing from Boston's RA Capital Management will support company operations and the continued development of Secretome’s pipeline of innovative treatments, including STM-01, an nCPC-derived therapy in development for treating Duchenne muscular dystrophy, which has had few therapeutic options.
MORE
Secretome Therapeutics Appoints New Chief Medical Officer
by | Apr 23, 2025
Michelle Smith Warren, MD, is a highly experienced pharmaceutical executive with more than two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases, Secretome said.
MORE